THERAPEUTICS RESEARCH ON AIDS-ASSOCIATED OPPORTUNISTIC INFECTIONS ADDENDUM TO PA-99-124 Release Date: November 10, 1999 NOTICE: AI-00-001 National Institute of Allergy and Infectious Disease Application Receipt Dates: January 2, May 1, September 1 This notice is an addendum to expand the research objectives that are responsive to PA-99-124, "Therapeutics Research on AIDS-Associated Opportunistic Infections," which was published in the NIH Guide for Grants and Contracts, July 9, 1999. This addendum also includes an addition to mechanism of support, and an addition to other interested institutes within NIH. Addition to MECHANISM OF SUPPORT INFORMATION The following is added: The number of R03 amended applications is limited to one. Addition to RESEARCH OBJECTIVES The following opportunistic pathogen is added: Pneumocystis carinii pneumonia (PCP) remains a major cause of morbidity and mortality in HIV-infected persons despite the use of the available prophylactic agents and more effective antiretroviral drugs. For individuals who cannot tolerate the preferred agent for prevention of PCP, trimethoprim-sulfamethoxazole (TMP/SMZ), alternative regimens are available and include aerosolized pentamidine, dapsone, and atovaquone. However, all these alternatives are significantly less effective than TMP/SMZ. Should current antiretroviral therapy failures become more widespread, PCP could again emerge as a frequent life-threatening complication. In addition, successful therapy may become more difficult to achieve if P. carinii strains resistant to sulfonamides and dapsone become progressively more common. Addition to INQUIRIES The National Heart, Lung, and Blood Institute (NHLBI) has additional interest in supporting research on the pulmonary, cardiovascular and hematologic aspects of opportunistic infections associated with HIV infection. The National Institute of Dental and Craniofacial Research (NIDCR) has additional interest in opportunistic infections in the oral cavity. The following Institute is added as a sponsor of this PA: The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has an interest in supporting research on the influence of opportunistic pathogens on the enterocytes in the gastrointestinal tract as well as the hepatocytes in the liver in disease expression. Therefore, applications of mutual interest are likely to be given a secondary assignment to NIDDK in accordance with the NIH referral guidelines. Inquiries regarding NIDDK programmatic issues may be directed to: Frank A. Hamilton, M.D., MPH Chief, Digestive Diseases Program Branch DDDN/NIDDK Natcher Building 45, Room 6AN12B National Institutes of Health 45 Center Drive MSC 6600 Bethesda, MD 20892 Telephone: 301-594-8877 FAX: 301-480-8300 Email: [email protected] INQUIRIES Direct inquires regarding programmatic issues to: Chris Lambros, Ph.D. Division of AIDS Room 5227 NIAID/NIH 6700-B Rockledge Drive, MSC 7624 Bethesda, MD 20892-7624 Telephone: 301-435-3769 FAX: 301-402-3171 Email: [email protected] Direct inquiries regarding fiscal and administrative matters to: Ms. Linda M. Shaw Division of Extramural Activities Room 2125 NIAID/NIH 6700-B Rockledge Drive, MSC 7614 Bethesda, MD 20892-7614 Telephone: 301-402-6611 FAX: 301-480-3780 Email: [email protected]

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices


NIH Office of Extramural Research Logo
   Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS) 		  USA.gov - Government Made Easy
NIH... Turning Discovery Into Health®